Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.

FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy

Iron deficiency represents more than a medical condition; it is a reflection of persistent health disparities, according to an editorial published in The Lancet Haematology.

A Case for Iron Deficiency as a Marker of Inequality in Care Access and Treatment

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

In-Room Air Purifiers Could Impact RSV Incidence Among Older Adults

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.

Addressing Patent Hurdles, Payer Barriers, and Interchangeability

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

AJMC Post Conference Perspectives: ESC Congress 2024: Updates in Managing Heart Failure

Unmet Needs in the HFmrEF and HFpEF Landscape

Video content above is prompted by the following:

Based on the new data from the 3 abstracts, what unmet needs could the therapies address within the heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF landscape?

Videos

® Post Conference Perspectives from European Society of Cardiology Congress 2024 in London, United Kingdom, focusing on key updates in heart failure management, including the implications of the FINEARTS-HF trial findings on finerenone, the role of β-blockers and dapagliflozin, and the need to address unmet needs in treatment strategies for patients with mildly reduced and preserved ejection fractions.

Javed Butler, MD, MPH, MBA, discusses the FINEARTS-HF trial presented at European Society of Cardiology Congress 2024, highlighting its objective to evaluate finerenone in patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, the randomized design, and results indicating a reduction in worsening HF events compared with placebo.



Overview of FINEARTS-HF Trial

Javed Butler, MD, MPH, MBA, discusses the current mineralocorticoid receptor antagonists (MRAs) used for heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, emphasizing the role of nonsteroidal MRAs such as finerenone, and explore how the FINEARTS-HF results could translate into real-world benefits and inform the clinical pathway for these patients.

Role of MRAs in HFmrEF and HFpEF

Javed Butler, MD, MPH, MBA, discusses the data from European Society of Cardiology Congress 2024 on β-blocker use in patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, focusing on the study’s objective, design, and methodology as well as key results and takeaways regarding the role of β-blockers in the multimodal management of these HF types.

Overview of BB Use and Outcomes in HFmrEF and HFpEF 

Javed Butler, MD, MPH, MBA, discusses the additional benefits of combining finerenone with sodium-glucose cotransporter-2 inhibitors for treating heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF as well as how a multimodal approach used in HF with reduced EF can be adapted for managing these conditions.


Multi-Modal Treatment Strategy for HFmrEF and HFpEF

Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.

Overview of DAPA ECHO Trial

Emerging therapies for heart failure with midrange and preserved ejection fraction (HFmrEF and HFpEF) aim to address significant unmet needs in these patient populations. Current treatments often fall short in effectively managing symptoms and improving outcomes for these subtypes of heart failure. The new data from recent abstracts suggest that novel therapeutic approaches could enhance patient quality of life, reduce hospitalization rates, and potentially improve survival. These therapies may also offer more personalized treatment options, addressing the diverse pathophysiological mechanisms underlying HFmrEF and HFpEF.

Unmet Needs in the HFmrEF and HFpEF Landscape

EP: 1.Overview of FINEARTS-HF Trial

EP: 2.Role of MRAs in HFmrEF and HFpEF

EP: 3.Overview of BB Use and Outcomes in HFmrEF and HFpEF

EP: 4.Multi-Modal Treatment Strategy for HFmrEF and HFpEF

EP: 5.Unmet Needs in the HFmrEF and HFpEF Landscape

EP: 6.Overview of DAPA ECHO Trial